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Abstract
Yellow nail syndrome (YNS; OMIM 153300, ORPHA662) is a very rare disorder that almost always occurs after 50 years of
age but a juvenile or familial form has also been observed. YNS is diagnosed based on a triad associating yellow nail
discoloration, pulmonary manifestations (chronic cough, bronchiectasia, pleural effusion) and lower limb lymphedema.
Chronic sinusitis is frequently associated with the triad. YNS etiology remains unknown but a role of lymphatic
impairment is usually evoked. YNS is more frequently isolated but may be associated in rare cases with autoimmune
diseases, other clinical manifestations implicating lymphatic functions or cancer and, hence, is also considered a
paraneoplastic syndrome. YNS management is symptomatic and not codified. YNS can resolve spontaneously.
Oral vitamin E alone or even better when associated with triazole antifungals may achieve partial or total
disappearance of nail discoloration. Pleural effusion can be treated surgically, with decortication/pleurectomy or
pleurodesis. Antibiotic prophylaxis is prescribed for bronchiectasia with chronic sputum production. Lymphedema
treatment is based on low-stretch bandages and the wearing of elastic compression garments combined with
skin care, exercises and, as needed, manual lymph drainage.
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Background
The first case of yellow nail syndrome (YNS; OMIM
153300, ORPHA662) was probably reported by Heller
in 1927 [1], but Samman & White described the first
series of patients who had yellow nails associated with
lymphedema in 1964 [2]. That report included 13 pa-
tients (six men, seven women; age range at onset 25–65
years), all of whom had very slow measured nail growth
associated with abnormal nail-plate discoloration, ran-
ging from pale yellow to dark greenish, and frequent
onycholysis. Eight of them had ankle edema; one
patient each had facial edema or Milroy’s disease
(familial form of primary lymphedema). Four patients’
limb lymphangiograms showed lymphatic abnormal-
ities, such as tortuous, dilated or hypoplastic vessels,
which the authors considered suggestive of lymphatic
dysfunction or defective lymph drainage being respon-
sible for YNS. In this review, we analyze the available
literature on this subject, describing clinical character-
istics, explorations, associated diseases and manage-
ment of this rare syndrome.
Methodology
The literature search of the PubMed database used the
words “yellow nail syndrome” for articles written in
English or French. Other references cited in the identi-
fied articles were also considered.
Definition
YNS is characterized by a triad of thickened yellow
nails, primary lymphedema and respiratory manifesta-
tions. It is an acquired condition of unknown etiology.
It is a syndrome – not a disease – that is associated
with conditions as different as diseases implicating the
lymphatic system, autoimmune diseases or cancers.
Whereas Samman & White’s first description of YNS
included only nail discoloration, Emerson added pleural
effusion to the diagnostic criteria [3]. Among the three
clinical YNS characteristics (yellow nail syndrome, re-
spiratory tract involvement, lymphedema), only two are
required to diagnose YNS but it is difficult to call the
entity YNS without nail abnormality [4]. Moreover, the
three components are not necessarily present simultan-
eously, and may appear individually and sequentially,
thereby making YNS diagnosis difficult. The complete
triad is present only in 27–60% of the patients [5–10]
(Table 1). The percentage differences of a given clinical
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manifestation may be attributed to the medical spe-
cialty that recruited the patients.
Epidemiology
No precise data are available to determine the exact
prevalence of YNS, as fewer than 400 cases have been
published in the literature, with an estimated prevalence
<1/1,000,000. Cases have been described in all countries
worldwide. YNS most often occurs in adults over
50 years old, with no sex predominance [5–7]. Pediatric
forms are very rarely reported [11–21]: YNS may be
present at birth (congenital) or develop before the age of
10 years [8].
A familial form of YNS has very rarely been described
[5, 22–24], affecting two siblings [25, 26] or a family
with eight cases in four sibships over two generations
[22]. The very few reported familial cases mimic a dom-
inant inheritance pattern, which is not supported by any
genetic evidence [5]. YNS may be associated with intel-
lectual disability, in which case it evokes a more com-
plex syndrome [25] or occurs in cases of consanguinity
[17].
Diagnosis and diagnostic methods
Yellow nails
Yellow nails are the main clinical manifestation leading
to YNS diagnosis. However, the possible interval be-
tween the first clinical sign (lymphedema, lung manifes-
tations) and nail discoloration hinders affirmation of the
YNS diagnosis. That yellowing represents a subset of
chromonychia, defined as pathological nail discolor-
ation, especially xanthonychia (yellow nail coloration).
Nail discoloration varies from pale yellow to more or
less dark greenish [27]. The nail plate becomes thick-
ened, with an enhanced transverse curvature (overcur-
vature), sometimes with a notable hump, cross-ridging,
very hard (scleronychia) and difficult-to-trim nail, and
cuticle disappearance [28]. Usually opaque, the lunula
disappears because of nail hyperkeratosis [27] (Fig. 1).
Erythema may be seen in the proximal nail fold, fre-
quently associated with chronic paronychia). Onycholy-
sis (distal nail plate–nail bed separation) may occur
with possible proximal spreading, leading to complete
nail shedding [29, 30]. Longitudinal growth of the
affected nail (0.23 mm per week) was half that of a nor-
mal nail (0.46 mm per week) [2, 31]. The affected nail’s
thickness (0.97 mm) was double that of a normal nail
(0.57 mm), suggesting that the nail that grows half as
fast and twice as thick [31].
Pulmonary manifestations
Lung involvement in YNS, which occurred in 56–71% of
the patients, diversely affected some parts of the respira-
tory tract with a variety of clinical manifestations [6–8].
Chronic cough is the most frequent pulmonary mani-
festation seen in 56% of YNS patients [6], with pleural
effusions found in 14–46% of the patients [6, 7].
Based on their retrospective systematic review of more
than 150 patients described in publications identified
with the search terms “pleural effusion” and “YNS”,
Table 1 YNS clinical manifestations found in six large series of patients
Manifestation Maldonado et al.
[6], N = 41
Hoque et al. [5],
N = 11
Piraccini et al. [7],
N = 21
Nordkild et al. [8],
N = 97
Varney et al. [9],
N = 17
Pavlidakey et al. [10],
N = 62
Yellow nails, n (%) 41 (100) 10 (91) 21 (100) 86 (89) 17 (100) 53 (85)
Chronic pulmonary
manifestations, n (%)
23 (56) 7 (64) 15 (71) 61 (63) 17 (100) 24 (39) (PEs only)
Lymphedema, n (%) 26 (63) 6 (55) 6 (29) 78 (80) 13 (76) 45 (72)
Sinusitis, n (%) 17 (41) 3 (27) 3 (14) NR 14 (83) 11 (18)
Complete triad ~60% 27% 29% NR 76% 27%
PEs pleural effusions, NR not reported
Fig. 1 Yellowing of all 10 (a) finger and (b) toe nails
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Valdés et al. recently reported the characteristics of these
pleural effusions [32]: 68.3% were bilateral; the fluid ap-
peared serous in 75%, milky (chylothorax) in 22% and
purulent (empyemas) in 3.5%; 95% of effusions were de-
scribed as exudates (median protein level: 4.2 g/dl) and
5% as transudates that harbored a median nucleated
cell count of 1540 cells/mm3 with 96% lymphocytic
predominance.
However, sputum bacteria (Pseudomonas aeruginosa,
Haemophilus influenzae, Streptococcus pneumoniae,
Moraxella catarrhalis) are the same in idiopathic and
YNS-associated bronchiectasias [33]. Recurrent pneu-
monias occur in 22% of the patients. Also, bilateral ap-
ical fibrosis, patchy alveolar infiltrates and cystic lesions
are very rarely observed in YNS patients [33, 34].
YNS patients’ pulmonary function test results are
usually normal or may indicate a moderate-to-severe
restrictive syndrome attributable to pleural effusions
[4]. Extremely rare patients may have mixed obstruct-
ive–restrictive syndrome or decreased diffusion cap-
acity [6]. Histological examination of pleural biopsies
revealed normal morphology or that of chronic fibrosing
pleuritis, and did not provide any further information; bi-
opsies are usually not contributive [32]. Bronchiectasias
are present in 44%. Chest computed-tomography (CT)
scan is the best imaging technique to diagnose bronchiec-
tasia, which, in YNS patients, is significantly less extensive,
severe and with lower bronchial wall thickness scores than
in matched idiopathic bronchiectasia patients [33].
Lymphedema
Lymphedema is a clinical feature of YNS, occurring in
29–80% of the reported series, and may be the first sign
of the disease in about one-third of them [6–8]. Lymph-
edema characteristics do not differ from those of pri-
mary lymphedema. It involves the lower limbs, especially
bilateral and below the knee (Fig. 2). The increased vol-
ume of the lymphedematous limb is caused by excess
lymph accumulation but also fibrosis resulting from
fibroblast stimulation and excess adipose tissue due to
adipocyte stimulation [35, 36]. Stemmer’s sign (inability
to pinch the skin on the dorsal side or the base of the
second toe) is pathognomonic of lymphedema and is
fibrosis-related. Superficial edema is responsible for the
more-or-less present pitting edema. Lymphedema is a
chronic disease, with a major tissular component leading
to incomplete reversibility under treatment. Although
cellulitis (erysipelas) is the main lymphedema complica-
tion, discomfort, esthetic prejudice and diminished qual-
ity of life also complicate the disease [37, 38].
Sinusitis
Acute or chronic rhinosinusitis is very common in
YNS patients, estimated between 14 and 83% [5–10].
The maxillary sinus is the most frequently affected,
followed by ethmoid, frontal and sphenoid [9] (Fig. 3).
Nasal symptom onset may precede nail changes by a
few years, appear simultaneously or arise subse-
quently. Clinical signs include daily mucopurulent rhi-
norrhea, nasal obstruction and frequent post-nasal
drip. Nasal airway examination usually finds narrowed
nasal pathways, mucosal inflammation with variable
enlargement of the turbinates and the presence of
mucopus. Other symptoms may be associated, e.g.,
headaches or recurrent facial pain. Non-contrast sinus
CT scans show mucosal thickening, with fluid levels
sometimes reported.
Other manifestations
Very rare ocular involvement has been reported: che-
mosis, corneal micropannus (vascularized sheet of fi-
brous tissue overlying the cornea), eyelid lymphedema,
thickened conjunctiva [39, 40]. Anecdotal associations
have also been described: anhydrosis, pectus excava-
tum, eosinophilia–myalgia syndrome, bullous stoma-
titis, sarcoidosis and Raynaud’s phenomenon, cerebral
aneurysm and pancytopenia [6].
Fig. 2 Bilateral lower limb lymphedema involving the feet, ankles
and calves, with accentuation of the flexion folds
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Children
Among children with YNS, 75% had lung manifestations
(infections, pleural effusions, bronchial dilations and/or
bronchial cysts) and ear-nose-throat symptoms in 31%,
with a moderate female predominance [20]. Lymphedema
prevalence ranged from 56 to 80% of YNS children and
may appear later than the nail discoloration [8].
Pathogenesis
Although YNS etiology of remains unknown, some hy-
potheses were advanced. Lymphatic involvement is often
evoked to explain lymphedema, pleural effusion (particu-
larly chylothorax) or nail discoloration but it is difficult
to implicate it in bronchiectasia and sinusitis. Lymphatic
impairment is not easy to confirm. Four YNS patients
underwent lower limb direct lymphangiography, less
used at present, but lymphatic abnormalities were noted
only in the patient with severe lymphedema. Quantita-
tive limb lymphoscintigraphy with 99mTc-colloidal an-
timony sulfide revealed less activity (percentage uptake)
in the draining lymph nodes (inguinofemoral or axillary)
[41]. Moreover, the uptake percentages in the axillary/in-
guinal lymph nodes of the YNS group were significantly
lower than those of the normal controls but significantly
higher than those of subjects with primary or secondary
lymphedema, hence more suggestive of impaired lymph
transport than the lymphatic hypoplasia/aplasia seen in
true primary lymphedema. Furthermore, the YNS group
without lower limb edema had better lymphatic drainage
than those with edema [42] (Fig. 4). Maldonado et al.
thought that YNS pathophysiology might be attributable
to microvasculopathy associated with protein leakage ra-
ther than functional lymphatic impairment [43]. Notably,
nailfold capillaroscopy occasionally showed dilated and
tortuous capillary loops [44].
Defective lymphatic drainage might be responsible for
the slow growth and thickened nails observed in YNS,
and may reflect subungual tissue sclerosis leading to
lymphatic obstruction. Light microscopy examination of
sections of nail-matrix tissue revealed replacement of
the normally loose fibrovascular subungual stroma by
dense, fibrous tissue (composed of dense collagen de-
posits) extending from the immediate subepithelial
stroma to a depth of 2.5 mm. Numerous ectatic,
endothelium-lined channels were prominent within the
fibrotic stroma [45]. Fibrosis and dilated lymphatic ves-
sels were also seen in the parietal pleura of a YNS pa-
tient [46, 47]. The accumulation of lipofuscin pigment
was advanced to explain the yellow discoloration [48],
whereas abnormal nail keratinization might be ex-
plained by the presence electron microscopy-visualized
keratohyalin granules, not found in normal adult nails.
More recently, it was hypothesized that titanium, es-
pecially titanium dioxide, might play a role in YNS.
High titanium levels (determined by energy dispersive
X-ray fluorescence) were detected in the nails of YNS
patients but not in control nails. The authors postu-
lated that titanium ions were released from titanium
implants (inlays, crown) in the teeth or jaws through
the galvanic action of amalgam or localized oxidative
action of fluorides [49–51]. Other sources of titanium
ions were also suggested: joint implants, surgical sta-
ples, foods (chewing gum to try to explain YNS in chil-
dren), medication excipients, cosmetics (sunscreen,
moisturizers, shampoo, toothpaste) [50, 52]. Titanium’s
Fig. 4 Lower-limb lymphoscintigraphy images were obtained
40 min after injecting 99mtechnetium-labeled colloidal albumin into
two patients with the complete YNS triad: moderate lymphostasis
and slightly decreased (a) or absent (b) inguinal lymph-node uptake
Fig. 3 Sinus computed-tomography scan: note the subtotal opacity
of the left maxillary sinus and ethmoidal sinusitis
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hypothetical role remains possible, but probably not
sufficient, because its presence in other organs (liver,
spleen, lymph nodes, lung) of autopsied patients was
not accompanied with nail yellowing [53].
Associated diseases
Several infants had YNS associated with non-immune
hydrops fetalis; this association is probably not fortuitous
[54]. Non-immune hydrops fetalis was present at birth
[20, 55]. A child with YNS had a brother who died of
non-immune hydrops fetalis, suggesting a possible rela-
tionship between the two diseases [17].
YNS is very rarely associated with primary intestinal
lymphangiectasia (Waldmann’s disease) (OMIM 152800,
ORPHA90362) or lymphedema–distichiasis syndrome
(OMIM 153400, ORPHA33001), suggesting that these en-
tities have overlapping characteristics, including lymphatic
impairment [56, 57]. Waldmann’s disease is characterized
by primary intestinal lymphangiectasia, with lymph leakage
into the bowel lumen leading to hypoalbuminemia, hypo-
gammaglobulinemia and lymphopenia [58]. Distichiasis is
defined as double or more rows of eyelashes localized on
the Meibomian gland orifices [59].
The YNS association with malignant disease raises the
hypothesis that it might be a paraneoplastic syndrome
but that notion remains controversial. The frequency of
cancer being diagnosed concurrently or closely there-
after in YNS patients was estimated at 4/41 [6] and 1/21
[7]. Various types of cancers were associated with YNS:
bronchial carcinoma [60, 61], breast [7, 62, 63], non-
Hodgkin lymphoma [64, 65], gallbladder [6, 66], larynx
[67], renal cell carcinoma [6], endometrium [68], melan-
oma [3], multiple myeloma after hematopoietic stem-cell
transplantation [69] or precancerous mycosis fungoides
[28]. The YNS-to-cancer-diagnosis interval ranges from
days to years, with gradual development of the complete
YNS triad [61].
YNS was occasionally associated with autoimmune
diseases [70], immunodeficiency disorders, such as com-
mon variable immunodeficiency, combined T- and B-cell
deficiency [70, 71], Guillain–Barré syndrome [72], neph-
rotic syndrome [73, 74], Hashimoto’s thyroiditis, severe
hypothyroidism or hyperthyroidism [75–77], xanthogra-
nulomatous pyelonephritis [78] and rheumatoid arthritis
even without thiol-analog use [79].
Immunological studies on YNS patients are very
scarce. Isolated case reports associated YNS with IgA
deficiency [22] or hypogammaglobulinemia [80]. Bokszc-
zanin & Levinson described a 57-year-old woman with
YNS and poor selective responses after vaccination
against Streptococcus pneumoniae and Haemophilus
influenzae [81], which might explain, in part, the recur-
rent lung or sinus infections in YNS. Gupta et al. re-
ported lymphopenia in two YNS patients (one with
common variable immunodeficiency) with low percent-
ages of CD4+ T cells, high percentages of CD8+ T cells
and severe naïve CD4+ and CD8+ T-cell deficits respon-
sible for muted T-cell responses to antigens. A suggested
mechanism for diminished naïve T-cell subsets might be
less thymus output (thymus involution and/or apoptosis)
[70]. It is of interest to note that, in another rare disease
with lymphatic abnormality, primary intestinal lymphan-
giectasia (Waldmann’s disease), immunological investiga-
tion results were similar to those of YNS patients [82].
Differential diagnosis of nail discoloration
Drugs
D-Penicillamine, bucillamine and tiopronin are three
thiol compounds used for long-term treatment of
rheumatoid arthritis. For the rare cases of drug-related
YNS, nail discoloration was the first manifestation in
88% of them, but it was less frequently associated with
pleural effusion and lymphedema than in YNS not drug-
related [83, 84]. Competitive inhibition of disulfide-
binding in keratin biosynthesis is postulated to explain
the major slowing of nail plate growth in bucillamine-
treated patients. Moreover, thiol drugs contain cysteine,
which is also a major nail component. After bucillamine
withdrawal, nail discoloration declined in over 90% of
the affected patients but lymphedema and pulmonary
manifestations were attenuated in only 30–35% [84].
Gold and methotrexate, also used to treat rheumatoid
arthritis, are less suspected of being associated with YNS
[85].
Infections
Nail yellowing is abnormal and may be attributable to
something other than YNS. Nail infection or mycosis
should be ruled out before considering YNS. Candida-,
Aspergillus- or dermatophyte-caused nail mycosis may
cause such discoloration. Pseudomonas aeruginosa, via
production of the blue–green pigments pyoverdin and
pyocyanin, may be responsible for chloronychia (green
rather than yellow nail discoloration) in the elderly [86].
Chloronychia is more common in homemakers, barbers,
dishwashers, bakers and medical personnel.
Others
In children and adults, differential diagnoses include
planus lichen, psoriasis or alopecia areata, chronic par-
onychia, onychogryphosis and acquired pachyonychia
[87–89]. Yellow nail discoloration may also have rare
local and toxic causes (Table 2) [90].
Treatment
YNS treatment is not codified. YNS may resolve in few
months without treatment [91] or, when it is a paraneo-
plastic syndrome, after cancer therapy [62].
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Yellow nail changes
The main aim is to improve the frequently unesthetic
nail appearance and associated pain, due, in part, to ony-
cholysis. A few drugs have been proposed to treat the
nail discoloration with inconsistent efficacy. None of the
following treatments can be recommended systematic-
ally to treat YNS.
Systemic treatments of yellow nails
Oral vitamin E is the only agent that successfully
treated YNS [48, 92–95]. Oral α-tocopherol (vitamin E)
was frequently prescribed at 1000–1200 IU/day, with
incomplete or inconstant efficacy. Norton’s hypothe-
sized, as follows, that vitamin E would be effective: lipo-
fuscin pigments, possibly responsible for nail yellowing,
are derived from colorless lipid precursors, transformed
by oxidation in tissue to produce varying degrees of yel-
low; vitamin E has proven in vitro antioxidant proper-
ties, and in vivo might protect cell membranes against
free-radical–mediated oxidative damage, thereby poten-
tially blocking lipofuscin-pigment production [48].
Although YNS is not caused by fungal infection, tri-
azole antifungals were regularly used to treat it. Itraco-
nazole, given at 400 mg/day for 1 week/month for
6 months, achieved only two mild attenuations and two
cures among eight patients (one relapsed after drug dis-
continuation) [96]. Among the 13 patients who took oral
fluconazole (300 mg once weekly) and oral α-tocopherol
(1000 IU/day), two benefited from clinical improvement
and 11 were considered clinical cures [97], without any
efficacy on other YNS manifestations. One of the hy-
potheses to explain that partial efficacy is based on azole
antifungal stimulation of linear nail growth [98, 99].
Oral zinc sulfate supplementation (300 mg daily) ob-
tained attenuation of nail yellowing or growth and
lymphedema after 8 months of treatment but no modifi-
cation of pulmonary manifestations [95].
Clarithromycin (400 mg/day, 6 years) successfully treated
one patient [100].
A patient with common variable immunodeficiency
treated with subcutaneous immunoglobulin mounted
good responses in terms of frequency of infections,
lymphedema and pleural effusions [70].
Local treatments
Intralesional steroids, such as topical triamcinolone acet-
onide (5 mg/ml/injection, 0.1–0.2 ml for each affected
nail), were proposed alone or combined with fluconazole
and vitamin E [92, 101].
In a first study published in 1991, Williams et al. pre-
scribed topical vitamin E; the treated nails improved
clinically and growth rates rose [94]. In a randomized
study using a vitamin E preparation (solution of
20,000 IU of tocopherol acetate/fluid ounce of safflower
oil) applied twice daily to the nails), no difference (ap-
pearance or nail growth) versus placebo was observed
after 6 months of administration [23].
Pulmonary manifestations
Symptomatic treatments are prescribed. Patients may re-
ceive antibiotics for acute exacerbation of bronchiectasia,
whereas, for patients with poor symptom control and/or
recurrent exacerbations, low-dose antibiotic prophylaxis,
such as oral azithromycin (usually 250 mg 3 times/week),
achieved attenuation of chest symptoms for the majority
of them [33]. Physiotherapy training (postural drainage,
chest physiotherapy, flutter valve), combined or not with
antibiotic prophylaxis, is also prescribed to help patients
self-manage their chronic expectoration.
Vaccinations against flu and pneumococci are strongly
recommended. Surgical intervention of recurrent and/or
large pleural effusions is useful: decortication/pleurect-
omy, pleurodesis (talc [47, 102], picibanil [103], quina-
crine [4]) and pleural–peritoneal shunts were the most
effective treatments of symptomatic pleural effusions
with, respectively, 89, 82 and 67% partial or complete re-
sponses [33].
Octreotide, a somatostatin analog, was also used to treat
YNS pleural effusions or chylous ascites and lymphedema,
and generated positive responses [47, 104–107]. Somato-
statin analogues reduce intestinal lipid absorption and
lower the triglyceride concentration in the thoracic duct in
animals [108]. Those actions could explain the diminution
of the chylous but not non-chylous effusions present in
most YNS patients. Octreotide was initially administered
subcutaneously (0.5 mg twice daily) to ensure safety,
followed by the long-acting repeatable formulation (30 mg
given once/month) with or without progressive dose dim-
inution [105, 107]. One initial octreotide responder became
“resistant”, suggesting tachyphylaxis to long-lasting treat-
ment, as previously described for acromegaly patients
receiving chronic treatment. Lanreotide, an alternative
somatostatin analog, may be useful for such cases [47, 109].
Lymphedema
Complete decongestive therapy, also called complex or
multimodal decongestive physiotherapy, is the term
proposed by Michael Földi in the 1980s to define
Table 2 Rare, usually work-related, local toxic causes of yellow
nail discoloration, from [90]
Epoxy systems: metaphenylenediamine, 4,4′-methylenedianiline
Flower handling
Pesticides: diquat, paraquat, dinitroorthocresol, dinobuton
Chromium salts
Dyestuffs: dinitrosalicylic acid, dinitrobenzene, dinitrotoluene, trinitrotoluene
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lymphedema treatment. This approach is divided into
two separate phases [110]. The first, intended to obtain
the most important lymphedema-volume reduction, is
comprised of several components: low-stretch bandage,
manual lymph drainage, skin/nail care (to detect and
eliminate potential sites of entry for infection) and ex-
ercises, each having its own specific objective and role
in limiting the impact of this disorder. The intensive
strategy of this stage aims to achieve 30–40%
lymphedema-volume reduction [111], eliminating only
the fluid component of lymphedema. The second phase
of complete decongestive therapy helps stabilize lymph-
edema volume over the long-term and is based on
wearing a high-pressure elastic garment, exercises, skin
care and, sometimes, manual lymph drainage [112].
Each patient should be offered several training sessions
in validated specific patient-education programs to
master the wrapping procedure and verify good under-
standing and implementation. Overnight bandaging at
least three times per week is recommended during
long-term maintenance. The aim of learning self-
bandaging is to improve the patient’s autonomy to
manage his/her own lymphedema [113].
Sinusitis
Treatment of acute sinusitis is based on antibiotics
(amoxicillin–clavulanate (1.5–3 g/day), or, in the case of
penicillin allergy, doxycycline (200 mg/day), fluoroquino-
lone (levofloxacin, 500 mg/day) or moxifloxacin (400 mg/
day)) for 5–7 days [114]. Treatment of chronic sinusitis is
not specific for YNS patients but global responses to med-
ications, including short-course oral antibiotics, topical in-
tranasal steroids, saline irrigation and topical or oral
decongestant, are poor [115]. Surgical procedures may be
necessary and are essentially based on endoscopic sinus
surgery (endoscopic middle meatal antrostomy, conven-
tional inferior meatal antrostomy) [116].
Prognosis
Spontaneous remission of the nail changes has been ob-
served in up to 30% of the YNS patients, regardless of
treatment [5]. Remission of nail changes was more likely
for fingernails than toenails, perhaps because of persist-
ent lower limb lymphedema, which might maintain the
presumed lymphatic pathophysiology [5]. More gener-
ally, the attenuated discoloration is not associated with
simultaneous regression of other systemic manifesta-
tions. In YNS associated with malignant disease, treat-
ment of the latter may lead to attenuation or
disappearance of the clinical YNS signs [62, 69]. In
Maldonado et al.’s study, 17 of the 37 patients with
available follow-up information died after a median of
82 months [6]. In that study, a Kaplan–Meier survival
curve estimated median survival at 132 months, shorter
than that of a paired-control population.
Conclusion
YNS is very rare disorder associating yellow nail discol-
oration, lung manifestations/sinusitis and lymphedema.
It is more frequently isolated but may be associated with
other diseases implicating the lymphatic system, auto-
immune diseases or cancers. Its etiology remains un-
known, although lymphatic impairment is regularly
evoked in the literature. Titanium is a more recent
hypothetical agent but so far remains unconfirmed to
explain the syndrome. YNS treatment is symptomatic
for each component: yellow nails, pulmonary manifesta-
tions/sinusitis, lymphedema. Vitamin E combined with
fluconazole, usually prescribed to treat yellow nails,
achieves partial or complete responses. Spontaneous
resolution is also possible. Research is required to better
understand and treat this rare and very poorly recog-
nized disease.
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